Compare Dishman Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs IPCA LABS - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA IPCA LABS DISHMAN PHARMA/
IPCA LABS
 
P/E (TTM) x 25.1 23.8 105.5% View Chart
P/BV x 3.3 8.5 39.3% View Chart
Dividend Yield % 0.7 0.1 466.1%  

Financials

 DISHMAN PHARMA   IPCA LABS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
IPCA LABS
Mar-19
DISHMAN PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs3741,042 35.9%   
Low Rs129590 21.8%   
Sales per share (Unadj.) Rs197.8298.6 66.2%  
Earnings per share (Unadj.) Rs21.235.0 60.6%  
Cash flow per share (Unadj.) Rs34.749.4 70.2%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.80.4 216.2%  
Book value per share (Unadj.) Rs179.9247.1 72.8%  
Shares outstanding (eoy) m80.69126.35 63.9%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x1.32.7 46.6%   
Avg P/E ratio x11.923.3 50.9%  
P/CF ratio (eoy) x7.216.5 43.9%  
Price / Book Value ratio x1.43.3 42.4%  
Dividend payout %9.48.6 110.0%   
Avg Mkt Cap Rs m20,306103,108 19.7%   
No. of employees `0000.813.4 6.2%   
Total wages/salary Rs m5,3557,874 68.0%   
Avg. sales/employee Rs Th19,252.72,807.0 685.9%   
Avg. wages/employee Rs Th6,459.5585.8 1,102.7%   
Avg. net profit/employee Rs Th2,064.1329.0 627.4%   
INCOME DATA
Net Sales Rs m15,96137,732 42.3%  
Other income Rs m265577 46.0%   
Total revenues Rs m16,22638,309 42.4%   
Gross profit Rs m4,1036,901 59.5%  
Depreciation Rs m1,0911,824 59.8%   
Interest Rs m944189 500.5%   
Profit before tax Rs m2,3345,465 42.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,042 59.8%   
Profit after tax Rs m1,7114,422 38.7%  
Gross profit margin %25.718.3 140.6%  
Effective tax rate %26.719.1 140.1%   
Net profit margin %10.711.7 91.5%  
BALANCE SHEET DATA
Current assets Rs m11,01823,778 46.3%   
Current liabilities Rs m9,51710,975 86.7%   
Net working cap to sales %9.433.9 27.7%  
Current ratio x1.22.2 53.4%  
Inventory Days Days110104 106.5%  
Debtors Days Days3566 52.8%  
Net fixed assets Rs m16,30420,368 80.0%   
Share capital Rs m161253 63.9%   
"Free" reserves Rs m12,90730,971 41.7%   
Net worth Rs m14,51631,224 46.5%   
Long term debt Rs m4,1891,409 297.4%   
Total assets Rs m29,80545,507 65.5%  
Interest coverage x3.530.0 11.6%   
Debt to equity ratio x0.30 639.8%  
Sales to assets ratio x0.50.8 64.6%   
Return on assets %8.910.1 87.9%  
Return on equity %11.814.2 83.2%  
Return on capital %17.517.3 101.2%  
Exports to sales %24.845.9 54.0%   
Imports to sales %3.716.6 22.5%   
Exports (fob) Rs m3,95617,308 22.9%   
Imports (cif) Rs m5966,266 9.5%   
Fx inflow Rs m4,95217,308 28.6%   
Fx outflow Rs m6976,266 11.1%   
Net fx Rs m4,25511,042 38.5%   
CASH FLOW
From Operations Rs m2,7864,923 56.6%  
From Investments Rs m-1,529-1,563 97.8%  
From Financial Activity Rs m-941-1,832 51.4%  
Net Cashflow Rs m3161,528 20.7%  

Share Holding

Indian Promoters % 61.4 45.9 133.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 11.4 32.5%  
FIIs % 12.7 25.3 50.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 17.4 127.0%  
Shareholders   46,261 36,892 125.4%  
Pledged promoter(s) holding % 35.8 2.1 1,671.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   DIVIS LABORATORIES  WOCKHARDT  AUROBINDO PHARMA  PANACEA BIOTECH  FDC  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Lower, Dow Futures Up by 18 Points(12:30 pm)

Share markets in India are presently trading marginally lower. The BSE Sensex is trading down by 17 points, flat at 48,064 levels.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS